Delaying Alzheimer’s is worth trillions
Executive Summary
New drugs to delay the onset of Alzheimer's disease by five years would have a social benefit to Americans of as much as $4 trillion over the next four decades, according to a study sponsored by Accelerate Cure and Treatments for Alzheimer's Disease. A drug delaying onset of disease by one year would produce a benefit worth $1.2 billion over the same period. These findings demonstrate the benefits to be gained by giving promising Alzheimer's treatments "the same priority review" accorded drugs for diseases such as cancer and HIV/AIDS, ACT-AD Chair Daniel Perry contends...
You may also be interested in...
Rethinking Alzheimer's: Mapping Out an Approval Process
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.